This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Huang, T.-S.
Right arrow Articles by Chen, B.-C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Huang, T.-S.
Right arrow Articles by Chen, B.-C.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, June 2008, p. 2226-2227, Vol. 52, No. 6
0066-4804/08/$08.00+0     doi:10.1128/AAC.00414-07
Copyright © 2008, American Society for Microbiology. All Rights Reserved.

In Vitro Activities of Linezolid against Clinical Isolates of Mycobacterium tuberculosis Complex Isolated in Taiwan over 10 Years {triangledown}

Tsi-Shu Huang,1,3,4 Yung-Ching Liu,1,4* Cheng-Len Sy,2 Yao-Shen Chen,2,5 Hui-Zin Tu,1 and Bao-Chen Chen1

Section of Microbiology, Dept. of Pathology and Laboratory Medicine,1 Section of Infectious Diseases, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan,2 Department of Medical Technology, Foo-Yin Institute of Technology, Kaohsiung, Taiwan,3 School of Medicine, National Yang-Ming University, Taipei, Taiwan,4 Graduate Institute of Environmental Education, National Kaohsiung Normal University, Kaohsiung, Taiwan5

Received 26 March 2007/ Returned for modification 15 October 2007/ Accepted 22 March 2008

Significant increases in the MIC90s of linezolid in multidrug-resistant Mycobacterium tuberculosis isolates were seen between the baseline period of 2001 to 2003 (0.5 µg/ml) and 2004 (2 µg/ml). The MICs were 4 µg/ml in three strains. Both fluoroquinolones (except levofloxacin) and kanamycin were found to have statistically significant degrees of concordance with linezolid.

* Corresponding author. Mailing address: Section of Infectious Diseases, Kaohsiung Veterans General Hospital, 386 Ta-Chung 1st Rd., Kaohsiung, Taiwan, Republic of China. Phone: 886 (07)3468169. Fax: 886 (07)3468296. E-mail: ycliu{at}vghks.gov.tw

{triangledown} Published ahead of print on 7 April 2008.

Antimicrobial Agents and Chemotherapy, June 2008, p. 2226-2227, Vol. 52, No. 6
0066-4804/08/$08.00+0     doi:10.1128/AAC.00414-07
Copyright © 2008, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Yew, W. W., Chang, K. C., Chau, C. H. (2009). Comment on: Daily 300 mg dose of linezolid for the treatment of intractable multidrug-resistant and extensively drug-resistant tuberculosis. J Antimicrob Chemother 64: 1119-1119 [Full Text]  
  • Dietze, R., Hadad, D. J., McGee, B., Molino, L. P. D., Maciel, E. L. N., Peloquin, C. A., Johnson, D. F., Debanne, S. M., Eisenach, K., Boom, W. H., Palaci, M., Johnson, J. L. (2008). Early and Extended Early Bactericidal Activity of Linezolid in Pulmonary Tuberculosis. Am. J. Respir. Crit. Care Med. 178: 1180-1185 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»